Document is current
Any future updates will be listed below
-
Authors
Reguiai, Ziad https://orcid.org/0000-0003-4844-3559
Ghislain, Pierre‑Dominique
Baudier, Emilie
Zraik, Aurita
Boyé, Thierry
-
Funding
Funding for this research was provided by:
LEO Pharma
- License Information
-
More Information
Article History
Received: 16 October 2025
Accepted: 9 December 2025
First Online: 23 December 2025
Declarations
:
: Prof Dr Pierre-Dominique Ghislain: speaker and hospital investigator for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Flen, Galderma, Janssen, LEO Pharma, Maruho, Meda, Menarini, MSD, Novartis, PellePharm, Pfizer, Serono, UCB and Viatris. Dr Thierry Boyé: Personal fees and grant (clinical research) Novartis, LEO Pharma, Janssen, Abbvie, Amgen, Lilly, UCB. Dr Ziad Reguiai: Abbvie, Almirall, Amgen, Celltrion, Boerhinger-Ingelheim, Bristol-Meyers-Squibb, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Medac, MSD, Novartis, Pfizer, UCB. Emilie Baudier: Employee of LEO Pharma Aurita Zraik: Employee of LEO Pharma.
: The study adhered to the principles of the Declaration of Helsinki and received protocol approval from local institutional review boards (IRBs). Written informed consent was obtained from all participants. The study protocol was approved by the Ethics Committee OUEST III on 13 May 2020 in France, and the Ethics Committees of UC Louvain on 3 February 2021 in Belgium. All patients included in the study provided their signed, informed consent to participate.
